CoreWeave stock to acquire Core Scientific in $9 billion all-stock deal

CoreWeave announced its intent to acquire Core Scientific in an all-stock transaction valued at approximately $9 billion, a move designed to vertically integrate data center operations. This acquisition is projected to eliminate $10 billion in lease overhead over 12 years and generate approximately $500 million in annual run rate cost savings by late 2027, strengthening CoreWeave's AI technology stack while remaining leverage neutral. While CoreWeave has demonstrated a 313% year-to-date return, its significant valuation has led to a recent BofA Securities downgrade to Neutral, despite positive operational developments including new hyperscaler customer agreements.

Analysis

CoreWeave (CRWV) has announced a definitive agreement to acquire Core Scientific in an all-stock transaction valued at approximately $9 billion. This strategic move aims to vertically integrate data center operations, a step described by Barclays as a natural evolution for the company. The acquisition is projected to yield significant financial benefits, including the elimination of $10 billion in lease overhead over 12 years and an estimated $500 million in annual run-rate cost savings by the end of 2027. The all-stock nature of the deal ensures it remains leverage neutral. However, this strategic enhancement is set against a backdrop of significant valuation concerns. The stock has posted a 313% year-to-date return, and BofA Securities recently downgraded its rating to Neutral, citing that the substantial rally has likely priced in much of the near-term upside, despite raising its price target to $185. This valuation pressure exists alongside strong operational momentum, evidenced by the deployment of NVIDIA's GB300 systems, new AI software product launches, and an expanded agreement with OpenAI.

Key Decisions for Investors

• Given CoreWeave's 313% year-to-date rally and the recent BofA downgrade on valuation grounds, investors should consider that the positive outlook from the Core Scientific acquisition may already be substantially priced into the stock.
• Shareholders should evaluate the long-term strategic merit of the acquisition, which vertically integrates the AI stack and is projected to deliver significant cost synergies, as a core tenet of a long-term holding thesis.
• Monitor key execution milestones, including regulatory approval for the acquisition, progress toward the Q4 2025 closing date, and subsequent financial reports for evidence of the projected $500 million in annual cost savings.
• Consider the high valuation multiples, as flagged by InvestingPro and BofA, as a primary risk factor that could lead to heightened volatility, particularly if operational execution or synergy realization falls short of expectations.